text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 51037-30-0 | Product Number: M2053


Purity: >98.0%(GC)
  • 2-Carboxy-5-methylpyrazine 4-Oxide
  • 5-Carboxy-2-methylpyrazine 1-Oxide
  • 5-Methylpyrazine-2-carboxylic Acid 4-Oxide
4   Contact Us 8  
≥20  Contact Us ≥20 

* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Product Number M2053
Purity / Analysis Method >98.0%(GC)
Molecular Formula / Molecular Weight C__6H__6N__2O__3 = 154.13  
Physical State (20 deg.C) Solid
Storage Temperature 0-10°C
Condition to Avoid Heat Sensitive
CAS RN 51037-30-0
Reaxys Registry Number 777471
PubChem Substance ID 135726995
Merck Index (14) 111
MDL Number


Appearance White to Almost white powder to crystal
Purity(GC) min. 98.0 %
Properties (reference)
Melting Point 180 °C
Solubility (soluble in) Methanol
Pictogram Pictogram
Signal Word Warning
Hazard Statements H319 : Causes serious eye irritation.
Precautionary Statements P264 : Wash skin thoroughly after handling.
P280 : Wear eye protection/ face protection.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Related Laws:
RTECS# UQ2453000
Transport Information:
HS Number 2933.99.8290
Acipimox: A Long-Acting Antilipemic Agent

Acipimox, a nicotic acid [N0082] analogue, is a long-acting antilipemic agent. It inhibits the release of non-esterified fatty acids from adipose tissue and reduces total serum triglyceride and cholesterol levels. These decrease occur in the in the very low density lipoprotein (VLDL) fraction and in the low density lipoprotein (LDL) fraction. In addition, acipimox increases high density lipoprotein (HDL) cholesterol. It is also reported to improve insulin sensitivity in diabetes. It is reported that acipimox acts on the nicotinic acid receptor, inhibiting the enzyme triglyceride lipase. (The product is for research purpose only.)


PubMed Literature

Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents